-
In 2022, the six major tracks of the pharmaceutical sector will have a high degree of prosperity
Time of Update: 2022-01-26
On the one hand, the global innovative drug projects in the clinical stage are accelerating, the demand for CDMO will continue to grow, and overseas orders will continue to be transferred to China, bringing huge market opportunities to domestic enterprises; on the other hand, with the API + preparations With the advancement of CDMO's integrated layout, the revenue generated by a single project is also expected to increase .
-
Inspection after strict control of drug costs is a big deal
Time of Update: 2022-01-26
Reducing the "medicine ratio" is to use the doctor's treatment method to replace the drug, which is relatively difficult; to reduce the "examination ratio" is to use the doctor's inspection method instead of the machine, which is relatively easy .
-
Liu Luxiang, vice president of Buchang Pharmaceuticals, resigns
Time of Update: 2022-01-26
On January 6, Buchang Pharmaceutical announced that the board of directors received a written resignation report submitted by the vice president of the company, Mr.
Liu Luxiang's resignation report will take effect from the date of delivery to the board of directors .
-
Under the general trend of innovation, 2 types of improved new drugs will usher in a research and development climax
Time of Update: 2022-01-26
In general, under the background of accelerated innovation and development of pharmaceutical companies, improved new drugs with obvious clinical advantages and less risk will usher in a "R&D outlet" with policy support .
-
44 proprietary Chinese medicine applications were withdrawn from the Internet, involving nearly 20 pharmaceutical companies
Time of Update: 2022-01-26
According to the notice, 44 drug product regulatory applications were withdrawn from the Internet, all of which were proprietary Chinese medicines, involving 19 Chinese medicine companies .
-
Under the drastic "price reduction" of centralized procurement, where is the way out for pharmaceutical companies?
Time of Update: 2022-01-26
Because of the cut-off of centralized procurement, a pharmaceutical factory in North China was included in the "violation list", and In the next 9 months, they cannot participate in the national centralized drug procurement activities .
-
"Top Student" LOXO-435 Among FGFR3 Inhibitors
Time of Update: 2022-01-26
LOXO-435 exhibits a broad therapeutic index in vivo [4]Preclinical data for LOXO-435Preclinical data for LOXO-435The kinase profile data in Figure 7 and subsequent data demonstrating the safety of the compound demonstrate that LOXO-435 is a potent, highly isoform-selective FGFR3 inhibitor with potency against FGFR3 gatekeeper resistance mutations; LOXO -435 can avoid the dose-limiting toxicity caused by inhibition of FGFR1 and FGFR2 - hyperphosphatemia and other adverse events of chronic intolerance .
-
Announcement of R&D expenses of 71 pharmaceutical companies: Yiling, Baiyunshan, China Resources Sanjiu...
Time of Update: 2022-01-26
Image source: WeChat public account "Pharmaceutical Aspects"Relevant people in the industry believe that according to the current development trend of new traditional Chinese medicines, the market size is expected to exceed one trillion yuan in 2022, and will reach 1.
-
In 2022, the number of innovative pharmaceutical companies landing in the capital market is expected to break through again
Time of Update: 2022-01-26
In addition, there is also an IPO application for an innovative drug company on the ChiNext Board of the Shenzhen Stock Exchange, namely Hualan Vaccine, which has also been submitted to the China Securities Regulatory Commission.
-
Yangzijiang's exclusive product rises 200%!
Time of Update: 2022-01-25
com, although the frequency of patient visits has been reduced due to the impact of the epidemic in 2020, there are still more than 10 gastric medicine products with sales of more than 100 million yuan in the terminal Chinese patent medicine market of public medical institutions in China.
-
Going overseas to develop into a pharmaceutical company is an inevitable choice, and challenges are coming
Time of Update: 2022-01-25
In recent years, with the continuous improvement of the research and development capabilities of domestic innovative pharmaceutical companies, the number of new drug license-out transactions in China has been increasing, and the transaction volume has also begun to hit new highs .
-
Lukang Pharmaceutical's Ticagrelor Tablets obtained the "Drug Registration Certificate"
Time of Update: 2022-01-25
On January 11, Lukang Pharmaceutical announced that it had received the "Drug Registration Certificate" (certificate number: 2021S01335) for Ticagrelor Tablets issued by the State Food and Drug Admini
-
Yunnan draws a 5-year development blueprint to build China's "medicine creation" highland
Time of Update: 2022-01-25
With the release of Yunnan Province's "14th Five-Year" pharmaceutical industry development plan, it will further help the high-quality development of the pharmaceutical industry including the traditional Chinese medicine industry .
-
At the beginning of 2022, the attention of the pharmaceutical industry has increased, and more than 460 institutions have received surveys
Time of Update: 2022-01-25
In response to the company's research and development, Xianju Pharmaceutical stated that the company will establish product groups in various therapeutic fields through market research and positioning to find and obtain the desired potential products, so as to ensure the company's continued stability in the next 5-10 years.
-
CSPC's anticancer drug "Mitoxantrone Hydrochloride Liposome Injection" was approved for marketing
Time of Update: 2022-01-25
Screenshot source: CDE official websiteAccording to CSPC's earlier announcement, the drug's NDA application in China is mainly based on the results of a pivotal, single-arm, multi-center Phase 2 study designed to evaluate the lipid profile of mitoxantrone hydrochloride Efficacy and safety of body injection in the treatment of relapsed/refractory peripheral T-cell and extranodal NK/T-cell lymphoma (NKTCL) .
-
List of Global mRNA Vaccine Patents
Time of Update: 2022-01-25
Source: Medicine Rubik's Cube NextPat Patent DatabaseAt present, two mRNA vaccines for the treatment of new crowns have been launched, one of which is Elasomeran (code-named mRNA-1273) developed by Moderna, which has been officially launched in Japan and Europe, and has obtained emergency use authorization in the United States.
-
Merck says it will significantly increase HPV vaccine supply to China in 2022
Time of Update: 2022-01-25
On January 11, according to the Financial Associated Press, Merck said that the company's HPV vaccine supply to China is increasing year by year, and will increase significantly in 2022 .
The Chinese people have had a strong demand for HPV vaccines in recent years .
-
Will the breakout of new pharmaceutical stocks become the norm?
Time of Update: 2022-01-25
On January 7th, Asieris Pharmaceuticals, a new stock listed on the Science and Technology Innovation Board, broke its offering at the opening and fell sharply by 12.
-
Over-evaluation of multiple products, the domestic antithrombotic drug market still has a lot of room for growth
Time of Update: 2022-01-25
For example, Sihuan Pharmaceutical recently announced that the antithrombotic drug ticagrelor tablets (60 mg and 90 mg) developed by the group have been approved for drug registration issued by the China National Medical Products Administration, which is deemed to have the same quality and efficacy as a generic drug.
-
NMPA issued an announcement to stop the production, sales and use of Lianbizhi injection from now on
Time of Update: 2022-01-25
For products that have been marketed, the holder of the drug marketing authorization is responsible for the recall, and the recalled products are supervised and destroyed by the local provincial drug supervision and administration department or take other measures such as harmless treatment in accordance with the law .
